Company news

BioCryst Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 15, 2025

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 13, 2025

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

BioCryst Appoints Steve Frank to Board of Directors

April 30, 2025

BioCryst to Report First Quarter 2025 Financial Results on May 5

April 20, 2025

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

February 23, 2025

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

February 23, 2025

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

February 11, 2025

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

February 9, 2025

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

February 9, 2025

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

January 9, 2025

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

November 17, 2024

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

October 23, 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4

October 20, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

October 13, 2024

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

October 9, 2024

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

October 1, 2024

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

September 29, 2024

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

September 5, 2024

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

September 4, 2024

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

BioCryst to Report Second Quarter 2024 Financial Results on August 5

July 21, 2024

ORLADEYO® (berotralstat) Approved in Peru

July 8, 2024

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

June 1, 2024

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 13, 2024

ORLADEYO® (berotralstat) Approved in Mexico

May 12, 2024

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

May 8, 2024

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

May 5, 2024

BioCryst to Report First Quarter 2024 Financial Results on May 6

April 21, 2024

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

April 16, 2024

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

February 25, 2024

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

February 22, 2024

BioCryst Launches ORLADEYO® (berotralstat) in Italy

February 18, 2024

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

February 11, 2024

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 4, 2024

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

January 4, 2024

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

December 18, 2023

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

November 28, 2023

BioCryst Launches ORLADEYO® (berotralstat) in Spain

November 20, 2023

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

November 9, 2023

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

November 2, 2023

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

November 2, 2023

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

October 26, 2023

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

October 25, 2023

BioCryst to Host R&D Day on November 3

October 19, 2023

BioCryst to Report Third Quarter 2023 Financial Results on November 2

October 18, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.